AbbVie leukemia treatment shows strong 9-year survival, remission benefits (opens in new tab)

AbbVie presented final Phase 3 CLL14 results for a fixed-duration venetoclax plus obinutuzumab regimen at the EHA 2026 Congress in Stockholm on 11-14 June. The randomized, open-label trial enrolled 432 previously untreated patients with coexisting conditions (n=216 per arm) and compared venetoclax plus obinutuzumab to obinutuzumab plus chlorambucil. After a median follow-up of 9.2 years, […] The post appeared first on <a href="